Skip to Content
scroll

ResMed Inc. (RMD) $29.08

Ozempic et al. have made the last year a particularly torrid and uncertain time for sleep apnoea company RMD. In simple terms, if these new wonder drugs lead to fewer people carrying weight, it will theoretically reduce the demand for RMD products. After bouncing over 40% from its panic 2023 low, we are contemplating trimming our 5% holding from purely a volatility perspective.

RMD
MM remains long and bullish towards RMD
Add To Hit List
chart
image description
ResMed Inc. (RMD)
image description

Relevant suggested news and content from the site

Back to top